Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

News

European Commission approves Cosentyx for the treatment of moderate-to-severe plaque psoriasis in children and adolescents. -Novartis

Novartis, announced the European Commission (EC) has granted the approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. the recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).

1 mins

News

Eli Lilly initiates phase III trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with NIAID.

Eli Lilly and Company announced the initiation of BLAZE-2, a Phase III trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities).

1 min

News

FDA accepts Vanda's applications for Hetlioz in the treatment of Smith-Magenis Syndrome.

Vanda Pharmaceuticals Inc. announced that the FDA has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS).

1 min

See all news

You may be interested in...

Conference

ICRMB 2021: International Conference on Reproductive Medicine and Biology

ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.

Conference

International Conference on Nephrology and Urology

ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.

Meeting

18th Meeting of the EAU Section of Oncological Urology

ESOU21 will take place in conjunction with the meeting of the EAU Section of Urological Research (ESUR). Thus it will be an opportunity to have collaborative sessions and knowledge exchange with our colleagues from this prestigious office of the EAU.